Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment

Article

关键词: BONE-MARROW NICHE;    CHRONIC MYELOGENOUS LEUKEMIA;    HEMATOPOIETIC STEM;    NOONAN-SYNDROME;    RECEPTOR GENE;    SHP2 PTPN11;    MOUSE MODEL;    MAINTENANCE;    PROGENITORS;    REGENERATION;   

DOI  :  10.1038/nature20131

来源: SCIE

【 摘 要 】

Germline activating mutations of the protein tyrosine phosphatase SHP2 (encoded by PTPN11), a positive regulator of the RAS signalling pathway(1), are found in 50% of patients with Noonan syndrome(2). These patients have an increased risk of developing leukaemia(3), especially juvenile myelomonocytic leukaemia (JMML), a childhood myeloproliferative neoplasm (MPN). Previous studies have demonstrated that mutations in Ptpn11 induce a JMML-like MPN through cell-autonomous mechanisms that are dependent on Shp2 catalytic activity(4-7). However, the effect of these mutations in the bone marrow microenvironment remains unclear. Here we report that Ptpn11 activating mutations in the mouse bone marrow microenvironment promote the development and progression of MPN through profound detrimental effects on haematopoietic stem cells (HSCs). Ptpn11 mutations in mesenchymal stem/progenitor cells and osteoprogenitors, but not in differentiated osteoblasts or endothelial cells, cause excessive production of the CC chemokine CCL3 (also known as MIP-1 alpha), which recruits monocytes to the area in which HSCs also reside. Consequently, HSCs are hyperactivated by interleukin-1 beta and possibly other proinflammatory cytokines produced by monocytes, leading to exacerbated MPN and to donor-cell-derived MPN following stem cell transplantation. Remarkably, administration of CCL3 receptor antagonists effectively reverses MPN development induced by the Ptpn11-mutated bone marrow microenvironment. This study reveals the critical contribution of Ptpn11 mutations in the bone marrow microenvironment to leukaemogenesis and identifies CCL3 as a potential therapeutic target for controlling leukaemic progression in Noonan syndrome and for improving stem cell transplantation therapy in Noonansyndrome-associated leukaemias.

【 授权许可】

Free